Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001342087 | SCV001535994 | likely pathogenic | Congenital myasthenic syndrome 4A | 2023-12-14 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with tryptophan, which is neutral and slightly polar, at codon 163 of the CHRNE protein (p.Ser163Trp). This variant is present in population databases (rs121909516, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with CHRNE-related conditions. ClinVar contains an entry for this variant (Variation ID: 1038740). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CHRNE protein function with a positive predictive value of 95%. This variant disrupts the p.Ser163 amino acid residue in CHRNE. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8755487). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Revvity Omics, |
RCV003145588 | SCV003830593 | uncertain significance | not provided | 2019-06-18 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV001825877 | SCV002093429 | uncertain significance | Congenital myasthenic syndrome | 2020-09-25 | no assertion criteria provided | clinical testing |